This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 2778 |
respiratory distress | 2497 |
distress syndrome | 2331 |
intensive care | 2263 |
lung injury | 1938 |
mechanical ventilation | 1856 |
critically ill | 1496 |
septic shock | 1117 |
care unit | 1108 |
ill patients | 1093 |
respiratory failure | 989 |
acute lung | 971 |
ards patients | 827 |
critical care | 598 |
risk factors | 577 |
patients admitted | 565 |
severe acute | 542 |
icu admission | 512 |
severe ards | 507 |
organ failure | 507 |
mg kg | 505 |
control group | 503 |
icu patients | 475 |
pao fio | 465 |
hospital mortality | 463 |
mechanically ventilated | 458 |
mortality rate | 454 |
cardiac arrest | 450 |
ml kg | 446 |
tidal volume | 442 |
two groups | 440 |
prone positioning | 421 |
apache ii | 405 |
inflammatory response | 391 |
membrane oxygenation | 375 |
icu stay | 373 |
extracorporeal membrane | 369 |
significantly higher | 361 |
stem cells | 361 |
mean age | 356 |
respiratory syndrome | 343 |
observational study | 342 |
coronavirus disease | 340 |
ventilated patients | 325 |
airway pressure | 323 |
critical illness | 317 |
severe sepsis | 314 |
sofa score | 309 |
care units | 302 |
nitric oxide | 301 |
induced lung | 299 |
blood pressure | 296 |
systematic review | 294 |
day mortality | 293 |
septic patients | 293 |
blood flow | 292 |
organ dysfunction | 288 |
gas exchange | 284 |
ali ards | 283 |
cohort study | 283 |
pulmonary edema | 278 |
clinical trial | 277 |
endothelial cells | 275 |
pg ml | 274 |
adult patients | 273 |
clinical trials | 272 |
statistically significant | 268 |
cardiac surgery | 267 |
ng ml | 264 |
prone position | 263 |
brain injury | 260 |
university hospital | 258 |
mesenchymal stem | 255 |
cardiac output | 252 |
arterial blood | 250 |
significant difference | 248 |
retrospective study | 248 |
arterial pressure | 246 |
ii score | 243 |
study period | 240 |
novel coronavirus | 240 |
present study | 238 |
ethics regulations | 238 |
driving pressure | 235 |
expiratory pressure | 231 |
multiple organ | 230 |
controlled trial | 228 |
significant differences | 227 |
cord uid | 227 |
renal failure | 227 |
doc id | 227 |
positive end | 223 |
logistic regression | 222 |
prospective study | 221 |
severe covid | 221 |
adult respiratory | 221 |
pulmonary vascular | 216 |
body weight | 215 |
extracellular vesicles | 214 |
randomized controlled | 213 |
icu mortality | 212 |
fio ratio | 205 |
renal replacement | 203 |
multivariate analysis | 200 |
spontaneous breathing | 200 |
informed consent | 199 |
patients received | 199 |
immune response | 199 |
central venous | 198 |
patients treated | 198 |
factors associated | 198 |
respiratory rate | 197 |
epithelial cells | 196 |
patients undergoing | 195 |
tidal volumes | 194 |
blood samples | 193 |
heart rate | 192 |
associated pneumonia | 191 |
patients receiving | 191 |
patients without | 190 |
replacement therapy | 190 |
risk factor | 190 |
growth factor | 189 |
emergency department | 188 |
respiratory system | 188 |
respiratory tract | 187 |
berlin definition | 186 |
type ii | 185 |
necrosis factor | 183 |
pulmonary artery | 183 |
kidney injury | 182 |
acute kidney | 179 |
statistical analysis | 179 |
cytokine storm | 178 |
saps ii | 177 |
care medicine | 177 |
endothelial cell | 176 |
gene expression | 175 |
hospital stay | 174 |
clinical practice | 172 |
stem cell | 170 |
animal models | 170 |
blood gas | 170 |
mean arterial | 169 |
inflammatory cytokines | 168 |
high mortality | 167 |
invasive mechanical | 167 |
tumor necrosis | 166 |
lung tissue | 165 |
mortality rates | 165 |
disease severity | 164 |
years old | 164 |
higher mortality | 164 |
high risk | 163 |
among patients | 162 |
median age | 162 |
clinical characteristics | 161 |
trauma patients | 160 |
included patients | 159 |
one patient | 159 |
bronchoalveolar lavage | 158 |
antibiotic therapy | 158 |
virus infection | 157 |
increased mortality | 157 |
heart failure | 156 |
two patients | 154 |
performed using | 153 |
protective ventilation | 152 |
significantly lower | 152 |
traumatic brain | 151 |
adverse events | 150 |
oxygen saturation | 150 |
hospital discharge | 149 |
invasive ventilation | 148 |
immune system | 147 |
lung disease | 147 |
increased risk | 147 |
plateau pressure | 146 |
clinical course | 145 |
diffuse alveolar | 142 |
clinical outcomes | 140 |
vascular permeability | 140 |
icu discharge | 139 |
mg dl | 138 |
acute phase | 137 |
pulmonary hypertension | 137 |
respiratory mechanics | 136 |
first hours | 135 |
inclusion criteria | 135 |
regression analysis | 135 |
syndrome coronavirus | 134 |
consecutive patients | 133 |
alveolar damage | 133 |
within hours | 133 |
signifi cant | 133 |
poor outcome | 133 |
alveolar epithelial | 133 |
primary outcome | 133 |
may also | 132 |
mm hg | 132 |
induced ards | 132 |
prospective observational | 131 |
life support | 131 |
first days | 131 |
signifi cantly | 131 |
reactive protein | 131 |
cardiac index | 131 |
bone marrow | 129 |
data suggest | 128 |
independently associated | 128 |
significant increase | 127 |
cell types | 127 |
plasma levels | 127 |
hospitalized patients | 125 |
acquired pneumonia | 125 |
inflammatory mediators | 125 |
vascular resistance | 124 |
patients died | 124 |
significantly increased | 124 |
lower respiratory | 123 |
related ards | 123 |
ventilatory support | 122 |
univariate analysis | 122 |
pressure support | 121 |
low tidal | 121 |
fi rst | 120 |
converting enzyme | 119 |
clinical features | 119 |
free days | 119 |
clinical studies | 119 |
pulmonary embolism | 118 |
important role | 117 |
previous studies | 117 |
myocardial infarction | 117 |
pulmonary fibrosis | 116 |
least one | 115 |
lung inflammation | 115 |
blood gases | 115 |
cardiogenic shock | 114 |
left ventricular | 114 |
immune cells | 113 |
controlled trials | 113 |
ethics committee | 113 |
peripheral blood | 113 |
induced acute | 113 |
shock patients | 113 |
severe respiratory | 112 |
lung function | 112 |
respiratory syncytial | 112 |
lung compliance | 112 |
survival rate | 111 |
ct scan | 111 |
lactate levels | 110 |
ml min | 110 |
kg min | 110 |
oxygen therapy | 110 |
surgical patients | 110 |
long term | 110 |
lung recruitment | 110 |
syncytial virus | 109 |
acute renal | 109 |
pulmonary disease | 109 |
oxidative stress | 109 |
side effects | 108 |
patients requiring | 108 |
systemic inflammatory | 108 |
month period | 108 |
group i | 107 |
odds ratio | 107 |
clinical data | 107 |
carbon dioxide | 106 |
endotracheal tube | 105 |
influenza virus | 105 |
interquartile range | 104 |
right ventricular | 104 |
viral infection | 104 |
significantly associated | 103 |
nosocomial infections | 103 |
confidence interval | 103 |
systemic inflammation | 102 |
icu length | 102 |
pilot study | 102 |
patients hospitalized | 102 |
alveolar macrophages | 101 |
three patients | 101 |
high levels | 101 |
significantly reduced | 101 |
vascular endothelial | 101 |
hypoxemic respiratory | 101 |
sample size | 101 |
year period | 101 |
pseudomonas aeruginosa | 100 |
endothelial barrier | 100 |
dead space | 100 |
plasminogen activator | 100 |
united states | 99 |
lung biopsy | 99 |
severe disease | 99 |
significantly different | 98 |
data collection | 98 |
computed tomography | 98 |
neutrophil extracellular | 98 |
exclusion criteria | 98 |
prospective cohort | 98 |
obese patients | 98 |
randomized clinical | 97 |
within days | 97 |
respiratory support | 97 |
healthy controls | 97 |
predictive value | 96 |
retrospective analysis | 96 |
retrospective cohort | 96 |
case series | 95 |
ventilator settings | 95 |
tfr cells | 94 |
hospital admission | 94 |
pediatric intensive | 94 |
lung ultrasound | 94 |
partial pressure | 94 |
ex vivo | 93 |
corticosteroid therapy | 93 |
renal function | 93 |
acute pancreatitis | 93 |
hospital cardiac | 93 |
viral infections | 92 |
serum levels | 91 |
open lung | 91 |
poor prognosis | 90 |
fl uid | 90 |
cytokine release | 90 |
failure assessment | 90 |
demographic data | 89 |
ards group | 89 |
noninvasive ventilation | 89 |
corticosteroid treatment | 89 |
independent risk | 88 |
beneficial effects | 88 |
statistical significance | 88 |
randomised controlled | 88 |
hemorrhagic shock | 88 |
pulmonary surfactant | 88 |
glasgow coma | 87 |
cell death | 87 |
results suggest | 87 |
study group | 86 |
standard deviation | 86 |
type i | 86 |
platelet count | 85 |
ecmo support | 85 |
four patients | 85 |
cell surface | 85 |
treg cells | 85 |
flow cytometry | 85 |
acute physiology | 85 |
lung volume | 85 |
th day | 84 |
pulmonary function | 84 |
pediatric patients | 83 |
severe hypoxemia | 83 |
neurological outcome | 83 |
patients included | 83 |
health care | 83 |
significant correlation | 83 |
clinical outcome | 83 |
pulmonary arterial | 83 |
measured using | 83 |
five patients | 83 |
blood glucose | 82 |
overall mortality | 82 |
extracellular traps | 82 |
patients suffering | 82 |
significant decrease | 82 |
innate immune | 82 |
whole blood | 82 |
protective effect | 81 |
healthy volunteers | 81 |
additional file | 81 |
requiring mechanical | 80 |
clinical signs | 80 |
medical icu | 80 |
age years | 80 |
case report | 80 |
inhaled nitric | 80 |
inflammatory responses | 80 |
cytokine production | 80 |
infected patients | 79 |
lavage fluid | 79 |
adhesion molecules | 79 |
recent study | 79 |
mouse model | 79 |
endotracheal intubation | 79 |
proinflammatory cytokines | 79 |
blood loss | 79 |
may contribute | 79 |
parenteral nutrition | 78 |
positive airway | 78 |
fluid responsiveness | 78 |
stroke volume | 78 |
liver transplantation | 78 |
red blood | 78 |
lung protective | 78 |
hemodynamic parameters | 78 |
heart disease | 77 |
inspired oxygen | 77 |
barrier function | 77 |
higher risk | 77 |
diff erence | 77 |
surfactant protein | 77 |
surgical icu | 77 |
commonly used | 77 |
sequential organ | 77 |
oxygen consumption | 76 |
may lead | 76 |
staphylococcus aureus | 76 |
disseminated intravascular | 76 |
prognostic factors | 76 |
chest ct | 75 |
coronary artery | 75 |
primary endpoint | 75 |
response syndrome | 75 |
chronic obstructive | 74 |
care med | 74 |
ejection fraction | 74 |
fluid balance | 74 |
per day | 74 |
intravascular coagulation | 74 |
enteral nutrition | 74 |
exogenous surfactant | 74 |
influenza pneumonia | 74 |
reactive oxygen | 73 |
several studies | 73 |
oxygen delivery | 73 |
average age | 73 |
alveolar type | 73 |
nlrp inflammasome | 73 |
recent studies | 73 |
collected data | 72 |
care patients | 72 |
lung diseases | 72 |
determine whether | 72 |
patients infected | 72 |
severity score | 72 |
cardiopulmonary bypass | 72 |
venous blood | 72 |
three groups | 72 |
data analysis | 71 |
controlled ventilation | 71 |
mg ml | 71 |
adverse effects | 71 |
surface area | 71 |
obstructive pulmonary | 71 |
regression model | 71 |
angiotensin ii | 71 |
randomized trial | 71 |
severe pneumonia | 71 |
six patients | 71 |
median time | 71 |
significantly decreased | 70 |
current study | 70 |
blood cultures | 70 |
extracorporeal life | 70 |
immune responses | 70 |
baseline characteristics | 70 |
arterial oxygen | 70 |
seven patients | 70 |
intubated patients | 69 |
study included | 69 |
analysis showed | 69 |
elderly patients | 69 |
acute hypoxemic | 69 |
consensus conference | 69 |
flow nasal | 69 |
significant reduction | 69 |
esophageal pressure | 69 |
reperfusion injury | 69 |
receiver operating | 69 |
glucocorticoid receptor | 68 |
blood cell | 68 |
nosocomial infection | 68 |
postoperative period | 68 |
high dose | 68 |
host defense | 68 |
patients showed | 68 |
supine position | 68 |
lower tidal | 68 |
patients will | 68 |
diff erent | 68 |
bacterial pneumonia | 68 |
patients underwent | 67 |
analyzed using | 67 |
acute myocardial | 67 |
study conducted | 67 |
chest radiograph | 66 |
eff ect | 66 |
host response | 66 |
blood transfusion | 66 |
cardiopulmonary resuscitation | 65 |
volume ventilation | 65 |
ii cells | 65 |
body mass | 65 |
per patient | 65 |
lung perfusion | 65 |
blood cells | 65 |
patient data | 65 |
study showed | 65 |
severity scores | 65 |
viral pneumonia | 65 |
group ii | 65 |
without ards | 65 |
linear regression | 65 |
intracranial pressure | 65 |
cd cd | 64 |
liver failure | 64 |
mesenchymal stromal | 64 |
minute ventilation | 64 |
kg day | 64 |
adhesion molecule | 64 |
patients developed | 64 |
enteral feeding | 64 |
widely used | 64 |
ards may | 64 |
nervous system | 63 |
cell proliferation | 63 |
pulmonary inflammation | 63 |
prognostic value | 63 |
cancer patients | 63 |
may improve | 63 |
hospital length | 63 |
bacterial infection | 63 |
kidney disease | 63 |
neuromuscular blockade | 63 |
patients may | 63 |
lung mechanics | 62 |
nasal cannula | 62 |
patients required | 62 |
protective effects | 62 |
time points | 62 |
differentially expressed | 62 |
cmv reactivation | 62 |
head injury | 62 |
beneficial effect | 61 |
individual patient | 61 |
mean duration | 61 |
venous pressure | 61 |
brain death | 61 |
blood culture | 61 |
oleic acid | 61 |
viral load | 61 |
co removal | 61 |
skeletal muscle | 61 |
inspiratory pressure | 61 |
lung water | 61 |
exact test | 61 |
injured lungs | 61 |
secondary outcomes | 61 |
tfr treg | 61 |
severe cases | 61 |
medical intensive | 60 |
authors declare | 60 |
release ventilation | 60 |
inflammasome activation | 60 |
medical records | 60 |
transpulmonary pressure | 60 |
chest wall | 60 |
leading cause | 60 |
pressure release | 60 |
alveolar space | 60 |
ascorbic acid | 60 |
system compliance | 60 |
pandemic influenza | 60 |
serum creatinine | 60 |
surface tension | 60 |
deep sedation | 60 |
year mortality | 60 |
lung epithelial | 60 |
pressure ventilation | 60 |
world health | 60 |
risk patients | 59 |
ischemic stroke | 59 |
patients aged | 59 |
mortality among | 59 |
ventilation strategy | 59 |
cell type | 59 |
dendritic cells | 59 |
stimulating factor | 59 |
increased significantly | 59 |
mass index | 59 |
venous catheter | 59 |
lung cancer | 58 |
author funder | 58 |
hemodynamic instability | 58 |
granted medrxiv | 58 |
lung damage | 58 |
fatty acids | 58 |
rescue therapy | 58 |
predicted body | 58 |
nutritional support | 58 |
one hundred | 58 |
patients presenting | 58 |
roc curve | 58 |
inflammatory cytokine | 57 |
tertiary care | 57 |
jugular vein | 57 |
associated ards | 57 |
teaching hospital | 57 |
cardiac function | 57 |
copyright holder | 57 |
tissue damage | 57 |
oxygen species | 57 |
continuous infusion | 57 |
herpes simplex | 57 |
median duration | 57 |
peep levels | 57 |
east respiratory | 57 |
early diagnosis | 57 |
one case | 56 |
time course | 56 |
clinical study | 56 |
multicenter study | 56 |
circulatory failure | 56 |
sex ratio | 56 |
plasma concentrations | 56 |
abdominal surgery | 56 |
public health | 56 |
middle east | 56 |
fluid clearance | 56 |
tracheal intubation | 56 |
early phase | 56 |
animal model | 56 |
european consensus | 56 |
study aimed | 56 |
potential therapeutic | 56 |
burn patients | 55 |
fluid resuscitation | 55 |
mononuclear cells | 55 |
inflammatory lung | 55 |
barrier dysfunction | 55 |
eight patients | 55 |
human lung | 55 |
induced ali | 55 |
endothelial permeability | 55 |
mortality risk | 55 |
previously described | 55 |
pulmonary oedema | 55 |
severe trauma | 55 |
lpv cds | 55 |
organ donation | 55 |
induced pulmonary | 55 |
multiple trauma | 54 |
may result | 54 |
health organization | 54 |
chain reaction | 54 |
gas analysis | 54 |
retrospective observational | 54 |
recruitment maneuver | 54 |
support ventilation | 54 |
placebo group | 54 |
refractory hypoxemia | 54 |
lung parenchyma | 54 |
normal range | 54 |
positive pressure | 54 |
major surgery | 54 |
nine patients | 54 |
observational studies | 54 |
polymerase chain | 54 |
interstitial pneumonia | 54 |
increased levels | 54 |
treatment group | 54 |
preliminary results | 54 |
international congresses | 54 |
ischemia reperfusion | 54 |
injury severity | 54 |
gram negative | 53 |
phase ii | 53 |
burn injury | 53 |
may help | 53 |
european society | 53 |
prolonged mechanical | 53 |
patient outcomes | 53 |
data collected | 53 |
three days | 53 |
developed ards | 53 |
stromal cells | 53 |
flow rate | 53 |
nursing staff | 53 |
term mortality | 53 |
surviving sepsis | 53 |
smooth muscle | 53 |
copd patients | 53 |
study population | 52 |
version posted | 52 |
intracranial hypertension | 52 |
cytokine levels | 52 |
eff ects | 52 |
cds tool | 52 |
may play | 52 |
animal studies | 52 |
previously reported | 52 |
assessed using | 52 |
diabetes mellitus | 52 |
operating characteristic | 52 |
first day | 52 |
progenitor cells | 52 |
tract infection | 52 |
artery catheter | 52 |
continuous variables | 52 |
monoclonal antibody | 52 |
pulmonary infection | 51 |
elevated levels | 51 |
coma scale | 51 |
wound healing | 51 |
blood lactate | 51 |
ill adults | 51 |
spontaneously breathing | 51 |
general hospital | 51 |
endothelial dysfunction | 51 |
dornase alfa | 51 |
days later | 51 |
predictive factors | 51 |
treated patients | 51 |
simplex virus | 51 |
organ system | 51 |
high frequency | 51 |
endothelial growth | 50 |
medical center | 50 |
recent years | 50 |
respiratory disease | 50 |
well tolerated | 50 |
icu admissions | 50 |
general anesthesia | 50 |
surfactant system | 50 |
pleural effusion | 50 |
high peep | 50 |
cell count | 50 |
single center | 50 |
patients compared | 50 |
high doses | 50 |
binding protein | 50 |
like receptor | 50 |
two different | 50 |
ten patients | 50 |
clinical presentation | 50 |
adipose tissue | 50 |
patient care | 50 |
reduce mortality | 50 |
mitochondrial dna | 50 |
investigate whether | 49 |
sofa scores | 49 |
patient population | 49 |
scoring system | 49 |
lung tissues | 49 |
room temperature | 49 |
chest radiography | 49 |
liver function | 49 |
patient safety | 49 |
post hoc | 49 |
two cases | 49 |
high incidence | 49 |
compared using | 49 |
antibiotic treatment | 49 |
mean apache | 49 |
mean values | 49 |
clinical manifestations | 49 |
required mechanical | 49 |
term outcomes | 49 |
innate immunity | 49 |
alveolar fluid | 49 |
major cause | 49 |
may reduce | 49 |
sepsis campaign | 49 |
oxygenation index | 49 |
patients presented | 48 |
even though | 48 |
healthy subjects | 48 |
ventilation strategies | 48 |
recruitment maneuvers | 48 |
every hours | 48 |
experimental studies | 48 |
central nervous | 48 |
lung edema | 48 |
activated protein | 48 |
control patients | 48 |
last years | 48 |
interstitial lung | 48 |
early stage | 48 |
supplementary material | 48 |
significant improvement | 48 |
chronic health | 48 |
oscillatory ventilation | 48 |
patient characteristics | 48 |
made available | 48 |
lung regions | 48 |
mechanical power | 48 |
respiratory infection | 47 |
per year | 47 |
clinically relevant | 47 |
family members | 47 |
rat model | 47 |
physiology score | 47 |
mean airway | 47 |
atrial fibrillation | 47 |
multivariate logistic | 47 |
descriptive study | 47 |
ml cmh | 47 |
one year | 47 |
common cause | 47 |
ii scores | 47 |
identifi ed | 47 |
hazard ratio | 47 |
epithelial cell | 47 |
white blood | 47 |
like syndrome | 47 |
emergency room | 47 |
considered statistically | 47 |
showed significant | 47 |
impedance tomography | 47 |
higher levels | 47 |
ill children | 47 |
pediatric ards | 47 |
may provide | 47 |
square test | 47 |
infected mice | 46 |
medical history | 46 |
lps stimulation | 46 |
associated acute | 46 |
amino acid | 46 |
chest radiographs | 46 |
tissue injury | 46 |
study protocol | 46 |
protein kinase | 46 |
simplified acute | 46 |
defi ned | 46 |
independent predictor | 46 |
oxide synthase | 46 |
airway pressures | 46 |
results indicate | 46 |
symptom onset | 46 |
lower mortality | 46 |
surgery patients | 46 |
disease progression | 46 |
cardiac failure | 46 |
severe patients | 46 |
intervention group | 46 |
body temperature | 46 |
diff erences | 46 |
influenza infection | 46 |
high morbidity | 46 |
therapeutic hypothermia | 46 |
negative bacteria | 46 |
rheumatoid arthritis | 46 |
observational cohort | 45 |
one study | 45 |
molecular weight | 45 |
infectious diseases | 45 |
decision making | 45 |
cause mortality | 45 |
blood volume | 45 |
remains neutral | 45 |
barrier integrity | 45 |
study design | 45 |
published maps | 45 |
acinetobacter baumannii | 45 |
hoc analysis | 45 |
lung fibrosis | 45 |
prospectively collected | 45 |
niv failure | 45 |
springer nature | 45 |
crit care | 45 |
randomly assigned | 45 |
significant changes | 45 |
frequency oscillatory | 45 |
antimicrobial therapy | 45 |
systolic blood | 45 |
jurisdictional claims | 45 |
functional status | 45 |
institutional affiliations | 45 |
neuromuscular blocking | 45 |
gene therapy | 45 |
standard care | 45 |
right ventricle | 45 |
fl ow | 45 |
nature remains | 45 |
extubation failure | 45 |
systolic function | 45 |
moderate ards | 45 |
study including | 44 |
selected patients | 44 |
therapeutic potential | 44 |
bal fluid | 44 |
findings suggest | 44 |
first week | 44 |
monoclonal antibodies | 44 |
written informed | 44 |
inflammatory cells | 44 |
per minute | 44 |
respiratory infections | 44 |
clinical research | 44 |
cell membrane | 44 |
improve survival | 44 |
health evaluation | 44 |
gold standard | 44 |
right heart | 44 |
improved survival | 44 |
extravascular lung | 44 |
results show | 44 |
airway management | 44 |
one hour | 44 |
med doi | 44 |
significant association | 44 |
propensity score | 44 |
peak inspiratory | 44 |
results showed | 44 |
peer review | 44 |
convalescent plasma | 44 |
electrical impedance | 43 |
respiratory viruses | 43 |
also found | 43 |
pneumoniae pneumonia | 43 |
ards due | 43 |
release syndrome | 43 |
review board | 43 |
early acute | 43 |
traditional tidal | 43 |
endothelial injury | 43 |
studied patients | 43 |
signaling pathway | 43 |
creatinine clearance | 43 |
improve oxygenation | 43 |
immune cell | 43 |
supportive care | 43 |
severely ill | 43 |
ecmo initiation | 43 |
alveolar recruitment | 43 |
underlying disease | 43 |
glass opacities | 43 |
critical patients | 43 |
cell therapy | 43 |
severe influenza | 43 |
neuromuscular blockers | 43 |
chronic kidney | 43 |
normal saline | 43 |
enrolled patients | 42 |
alveolar edema | 42 |
categorical variables | 42 |
higher peep | 42 |
ang ii | 42 |
berlin criteria | 42 |
icu los | 42 |
randomized trials | 42 |
higher incidence | 42 |
ill patient | 42 |
fluid administration | 42 |
significantly improved | 42 |
new zealand | 42 |
well known | 42 |
group compared | 42 |
first time | 42 |
groups according | 42 |
inflammatory diseases | 42 |
control groups | 42 |
escherichia coli | 42 |
endothelial damage | 42 |
tissue oxygenation | 42 |
subgroup analysis | 42 |
patients using | 42 |
hyaline membrane | 42 |
study demonstrated | 42 |
vena cava | 41 |
space fraction | 41 |
pulmonary endothelial | 41 |
signaling pathways | 41 |
prospective randomized | 41 |
future studies | 41 |
congenital heart | 41 |
amino acids | 41 |
dimer levels | 41 |
acute brain | 41 |
liver disease | 41 |
ecmo therapy | 41 |
may cause | 41 |
igg liposomes | 41 |
strongly associated | 41 |
respiratory symptoms | 41 |
dysfunction syndrome | 41 |
significantly elevated | 41 |
body surface | 41 |
activator inhibitor | 41 |
fluid management | 41 |
metabolic acidosis | 41 |
major trauma | 41 |
short term | 41 |
ill covid | 41 |
table shows | 41 |
organ damage | 41 |
total number | 41 |
two hours | 41 |
older patients | 41 |
included studies | 41 |
decreased significantly | 41 |
muscle weakness | 41 |
mycoplasma pneumoniae | 41 |
internal jugular | 41 |
expiratory flow | 40 |
blocking agents | 40 |
severe traumatic | 40 |
hand hygiene | 40 |
fluid challenge | 40 |
receptor antagonist | 40 |
phase i | 40 |
high level | 40 |
two studies | 40 |
remains unclear | 40 |
determined using | 40 |
early detection | 40 |
fatty acid | 40 |
another study | 40 |
fluid overload | 40 |
alveolar epithelium | 40 |
control study | 40 |
data will | 40 |
real time | 40 |
high flow | 40 |
nuclear factor | 40 |
severe head | 40 |
diagnostic criteria | 40 |
recombinant human | 40 |
cant diff | 40 |
study will | 40 |
key role | 40 |
hyaline membranes | 40 |
major role | 40 |
group showed | 40 |
organ failures | 40 |
sepsis syndrome | 40 |
bal samples | 40 |
infectious complications | 40 |
lactate level | 39 |
acute onset | 39 |
injured lung | 39 |
intravenous infusion | 39 |
regression models | 39 |
may increase | 39 |
identify patients | 39 |
therapeutic strategies | 39 |
cov infections | 39 |
failure due | 39 |
median length | 39 |
derived mesenchymal | 39 |
artery bypass | 39 |
time point | 39 |
transcription factor | 39 |
may explain | 39 |
clinical management | 39 |
molecular mechanisms | 39 |
also observed | 39 |
including patients | 39 |
three different | 39 |
controlled study | 39 |
renal dysfunction | 39 |
inflammatory process | 38 |
lps group | 38 |
time period | 38 |
positive correlation | 38 |
neutrophil elastase | 38 |
knockout mice | 38 |
receiving mechanical | 38 |
data regarding | 38 |
medical care | 38 |
continuous renal | 38 |
surgical intensive | 38 |
considered significant | 38 |
association studies | 38 |
pulmonary microvascular | 38 |
coronavirus pneumonia | 38 |
cox regression | 38 |
blood products | 38 |
therapeutic effects | 38 |
arterial oxygenation | 38 |
confidence intervals | 38 |
may occur | 38 |
injured patients | 38 |
eff ective | 38 |
case reports | 38 |
acute exacerbation | 38 |
edema fluid | 38 |
significantly correlated | 38 |
drug administration | 38 |
previous study | 38 |
task force | 38 |
lung transplantation | 38 |
peep cmh | 38 |
urine output | 38 |
large number | 38 |
success rate | 38 |
derived exosomes | 38 |
fibrin deposition | 38 |
systemic vascular | 38 |
small sample | 37 |
mcg kg | 37 |
organizing pneumonia | 37 |
positive blood | 37 |
lung collapse | 37 |
avian influenza | 37 |
rsv infection | 37 |
ec barrier | 37 |
mrna expression | 37 |
inflamed lungs | 37 |
hong kong | 37 |
therapeutic intervention | 37 |
care doi | 37 |
defense mechanisms | 37 |
institutional review | 37 |
cov infection | 37 |
continuous positive | 37 |
year old | 37 |
immunocompromised patients | 37 |
calculated using | 37 |
steady state | 37 |
receive either | 37 |
first three | 37 |
patients diagnosed | 37 |
bacterial infections | 37 |
fi ndings | 37 |
cecal ligation | 37 |
derived evs | 37 |
idiopathic pulmonary | 37 |
mean value | 37 |
relative risk | 37 |
acute pulmonary | 37 |
multiorgan failure | 37 |
icu survivors | 37 |
mitochondrial dysfunction | 36 |
venous thromboembolism | 36 |
hours later | 36 |
united kingdom | 36 |
rights reserved | 36 |
international license | 36 |
preliminary data | 36 |
icu nurses | 36 |
cardiac dysfunction | 36 |
failure requiring | 36 |
breathing trial | 36 |
data indicate | 36 |
blood vessels | 36 |
heart surgery | 36 |
care physicians | 36 |
blood mononuclear | 36 |
mixed venous | 36 |
organ injury | 36 |
end expiratory | 36 |
perfusion pressure | 36 |
least days | 36 |
successful weaning | 36 |
conventional ventilation | 36 |
rank test | 36 |
supplementary table | 36 |
see table | 36 |
respiratory insufficiency | 36 |
conventional mechanical | 36 |
pulse oximetry | 36 |
ards caused | 36 |
head trauma | 36 |
tissue factor | 36 |
controlled clinical | 36 |
severe lung | 36 |
secondary infections | 36 |
hydrogen peroxide | 36 |
center study | 36 |
competing interests | 36 |
protein levels | 36 |
coronavirus infection | 36 |
organ support | 36 |
hepatocellular carcinoma | 36 |
lung surfactant | 36 |
mortality benefit | 36 |
syndrome acute | 36 |
previous reports | 36 |
cardiogenic pulmonary | 36 |
jugular bulb | 36 |
cerebral perfusion | 36 |
cardiac injury | 35 |
volume expansion | 35 |
bilateral infiltrates | 35 |
different phenotypes | 35 |
bacterial sepsis | 35 |
note springer | 35 |
whitney test | 35 |
prospectively studied | 35 |
clinical evidence | 35 |
frequently used | 35 |
status epilepticus | 35 |
hospital day | 35 |
well established | 35 |
statistical analyses | 35 |
intravenous administration | 35 |
days post | 35 |
surgical procedures | 35 |
low levels | 35 |
sepsis patients | 35 |
final manuscript | 35 |
inflammatory markers | 35 |
routine use | 35 |
homeostatic corrections | 35 |
chronic respiratory | 35 |
infl ammatory | 35 |
urinary tract | 35 |
systemic circulation | 35 |
died within | 35 |
normal lung | 35 |
improved oxygenation | 35 |
sars patients | 35 |
klebsiella pneumoniae | 35 |
immune function | 35 |
high prevalence | 35 |
surface markers | 35 |
control subjects | 35 |
extracellular vesicle | 35 |
alveolar macrophage | 34 |
eligible patients | 34 |
traumatic stress | 34 |
vascular leakage | 34 |
spontaneous circulation | 34 |
related complications | 34 |
early identification | 34 |
intercellular adhesion | 34 |
commercially available | 34 |
reduced mortality | 34 |
pulmonary infiltrates | 34 |
following parameters | 34 |
poor outcomes | 34 |
thoracic society | 34 |
patients survived | 34 |
awake proning | 34 |
disease control | 34 |
supplemental oxygen | 34 |
general icu | 34 |
human lungs | 34 |
thermal injury | 34 |
three times | 34 |
peak airway | 34 |
inflammatory effects | 34 |
burned patients | 34 |
demographic characteristics | 34 |
pivotal role | 34 |
also showed | 34 |
hemodynamic monitoring | 34 |
willebrand factor | 34 |
heat shock | 34 |
patients enrolled | 34 |
cognitive dysfunction | 34 |
energy expenditure | 34 |
negative predictive | 34 |
coma score | 34 |
stress disorder | 34 |
aspiration pneumonia | 34 |
expression levels | 34 |
study shows | 34 |
weaning failure | 34 |
studies suggest | 34 |
endothelial glycocalyx | 33 |
term outcome | 33 |
scientific studies | 33 |
injury induced | 33 |
free radicals | 33 |
independent predictors | 33 |
normal values | 33 |
preterm infants | 33 |
experimental study | 33 |
fish oil | 33 |
inflammatory processes | 33 |
cystic fibrosis | 33 |
respiratory function | 33 |
pulmonary blood | 33 |
operating room | 33 |
studies showed | 33 |
ii pneumocytes | 33 |
following trauma | 33 |
healthy control | 33 |
differ significantly | 33 |
experimental model | 33 |
growth factors | 33 |
nosocomial pneumonia | 33 |
therapeutic interventions | 33 |
patient died | 33 |
stromal cell | 33 |
medrxiv preprint | 33 |
randomized study | 33 |
associated lung | 33 |
portal vein | 33 |
infl ammation | 33 |
ventilation mode | 33 |
central role | 33 |
correlation coefficient | 33 |
pulmonary vasoconstriction | 33 |
vascular endothelium | 33 |
antiviral therapy | 33 |
differential diagnosis | 33 |
human mesenchymal | 33 |
primary objective | 33 |
postoperative complications | 33 |
lps administration | 33 |
secondary analysis | 33 |
ventricular function | 33 |
increased morbidity | 33 |
pulse pressure | 33 |
subarachnoid hemorrhage | 33 |
positive predictive | 33 |
von willebrand | 33 |
general population | 33 |
patient outcome | 33 |
influenza viruses | 33 |
dependent lung | 33 |
acute care | 33 |
transforming growth | 33 |
patients ventilated | 33 |
adverse event | 33 |
study aims | 33 |
injury score | 33 |
arterial lactate | 33 |
ards cases | 33 |
longer duration | 33 |
common risk | 33 |
survival rates | 33 |
peep level | 33 |
sars coronavirus | 32 |
hospital death | 32 |
acquired weakness | 32 |
congestive heart | 32 |
pulmonary dysfunction | 32 |
lactate dehydrogenase | 32 |
days vs | 32 |
wide range | 32 |
lung endothelial | 32 |
days following | 32 |
murine model | 32 |
severe form | 32 |
therapeutic strategy | 32 |
analysis revealed | 32 |
previously healthy | 32 |
apache iii | 32 |
static compliance | 32 |
mild disease | 32 |
vivo lung | 32 |
abdominal muscle | 32 |
ards model | 32 |
factor alpha | 32 |
patienten mit | 32 |
vital signs | 32 |
complement activation | 32 |
trend towards | 32 |
hospital survivors | 32 |
low dose | 32 |
surfactant replacement | 32 |
study performed | 32 |
glucocorticoid treatment | 32 |
artery pressure | 32 |
lung microbiome | 32 |
lps challenge | 32 |
way anova | 32 |
organ function | 32 |
ventilator associated | 32 |
disease process | 32 |
bacterial translocation | 32 |
blood sample | 32 |
ards severity | 32 |
tnf production | 32 |
treatment strategies | 32 |
barrier enhancement | 32 |
increased vascular | 32 |
adult icu | 32 |
cardiovascular disease | 31 |
kg body | 31 |
abdominal sepsis | 31 |
better understanding | 31 |
healthcare workers | 31 |
chronic renal | 31 |
brain tissue | 31 |
early recognition | 31 |
right lung | 31 |
clinical decision | 31 |
macrophage activation | 31 |
laboratory data | 31 |
study suggests | 31 |
different respiratory | 31 |
research support | 31 |
control animals | 31 |
old male | 31 |
wistar rats | 31 |
medical university | 31 |
alveolar surfactant | 31 |
statistically signifi | 31 |
molecular patterns | 31 |
cerebral blood | 31 |
upper respiratory | 31 |
practice guidelines | 31 |
functional outcome | 31 |
blood vessel | 31 |
two independent | 31 |
improves oxygenation | 31 |
lung ventilation | 31 |
tertiary hospital | 31 |
extracorporeal co | 31 |
surfactant function | 31 |
initial dose | 31 |
support scientific | 31 |
admitted patients | 31 |
non invasive | 31 |
pathological findings | 31 |
potential role | 31 |
surfactant material | 31 |
icu care | 31 |
emergency medicine | 31 |
culture medium | 31 |
mean length | 31 |
inotropic support | 31 |
hepatic failure | 31 |
brain damage | 31 |
second group | 31 |
worse outcomes | 31 |
one week | 30 |
clinical diagnosis | 30 |
incidence rate | 30 |
patients whose | 30 |
serum concentrations | 30 |
developing ards | 30 |
increased pulmonary | 30 |
studies using | 30 |
taken together | 30 |
also known | 30 |
cell barrier | 30 |
standard treatment | 30 |
organ systems | 30 |
injury acute | 30 |
outcome measures | 30 |
negative correlation | 30 |
children admitted | 30 |
edema formation | 30 |
therapeutic target | 30 |
alveolar lavage | 30 |
oxygen tension | 30 |
plasma samples | 30 |
room air | 30 |
treated group | 30 |
outcome data | 30 |
mechanical ventilator | 30 |
cell injury | 30 |
respiratory parameters | 30 |
alveolar hemorrhage | 30 |
septic complications | 30 |
may benefit | 30 |
ct scans | 30 |
ards network | 30 |
high rate | 30 |
assess whether | 30 |
hypoxic pulmonary | 30 |
new therapeutic | 30 |
significant morbidity | 30 |
pulmonary injury | 30 |
clinical severity | 30 |
patient groups | 30 |
platelet counts | 30 |
platelet activation | 30 |
assisted ventilation | 30 |
lung involvement | 30 |
vasoactive drugs | 30 |
severe adult | 30 |
american thoracic | 30 |
acute circulatory | 30 |
sensitivity analysis | 30 |
residual capacity | 30 |
functional residual | 30 |
associated molecular | 30 |
seven days | 30 |
angiotensin converting | 30 |
lung weight | 30 |
transcription factors | 30 |
early stages | 30 |
transpulmonary thermodilution | 30 |
target genes | 30 |
type diabetes | 30 |
mechanical stretch | 30 |
also increased | 30 |
main cause | 30 |
dependent manner | 30 |
clinical condition | 30 |
identify factors | 30 |
lipid peroxidation | 30 |
muscle cells | 30 |
fio mmhg | 30 |
transthoracic echocardiography | 30 |
gene transfer | 30 |
flow oxygen | 30 |
clinical setting | 30 |
analysed using | 29 |
mild ards | 29 |
broad spectrum | 29 |
tissue oxygen | 29 |
venovenous ecmo | 29 |
epithelial injury | 29 |
therapeutic approach | 29 |
map mmhg | 29 |
immune dysfunction | 29 |
dr expression | 29 |
single dose | 29 |
ventilatory management | 29 |
acute inflammation | 29 |
gestational age | 29 |
class ii | 29 |
different types | 29 |
treatment options | 29 |
therapeutic targets | 29 |
membrane formation | 29 |
tract infections | 29 |
excluded patients | 29 |
high concentrations | 29 |
acute inflammatory | 29 |
light chain | 29 |
signal transduction | 29 |
less severe | 29 |
weaning process | 29 |
drug delivery | 29 |
good outcome | 29 |
inspiratory time | 29 |
respiratory drive | 29 |
alveolar spaces | 29 |
vitro studies | 29 |
syndrome patients | 29 |
adaptive immune | 29 |
studies reported | 29 |
evaluated using | 29 |
many patients | 29 |
negative pressure | 29 |
myocardial injury | 29 |
medical staff | 29 |
myosin light | 29 |
function tests | 29 |
evaluate whether | 29 |
undergoing cardiac | 29 |
small number | 29 |
loading dose | 29 |
present case | 29 |
new york | 29 |
serum lactate | 29 |
lymphocyte count | 29 |
prothrombin time | 29 |
time spent | 29 |
severe pulmonary | 29 |
rbc transfusion | 29 |
cell activation | 29 |
muscle mass | 29 |
effective treatment | 29 |
pulmonary circulation | 29 |
clinical conditions | 29 |
evidence suggests | 29 |
unfavorable outcome | 29 |
older age | 29 |
inflammatory reaction | 29 |
mean difference | 29 |
fold increase | 29 |
analysis using | 28 |
mortality compared | 28 |
quality improvement | 28 |
study found | 28 |
release phase | 28 |
hospital survival | 28 |
decreased mortality | 28 |
much higher | 28 |
arterial ph | 28 |
per se | 28 |
authors read | 28 |
protective mechanical | 28 |
acute coronary | 28 |
vascular dysfunction | 28 |
mortality associated | 28 |
severe forms | 28 |
colony stimulating | 28 |
severe tbi | 28 |
traumatic injury | 28 |
published data | 28 |
therapeutic effect | 28 |
sodium transport | 28 |
critical role | 28 |
cell transplantation | 28 |
observation period | 28 |
venous thrombosis | 28 |
among critically | 28 |
unit patients | 28 |
trial coordination | 28 |
protein expression | 28 |
regional lung | 28 |
ace expression | 28 |
respiratory acidosis | 28 |
vascular barrier | 28 |
plasma il | 28 |
gas flow | 28 |
confirmed covid | 28 |
ards mice | 28 |
venovenous extracorporeal | 28 |
primary cause | 28 |
therapeutic options | 28 |
ecmo patients | 28 |
every patient | 28 |
requiring icu | 28 |
serious adverse | 28 |
clinical use | 28 |
inflammatory effect | 28 |
discharged alive | 28 |
emergency medical | 28 |
relevant outcomes | 28 |
probably due | 28 |
iu ml | 28 |
glasgow outcome | 28 |
monocentric study | 28 |
average time | 28 |
apache score | 28 |
oxygen extraction | 28 |
laboratory findings | 28 |
survival benefit | 28 |
icu beds | 28 |
confi rmed | 28 |
left atrial | 28 |
fluid therapy | 28 |
ivc diameter | 28 |
scoring systems | 28 |
clinical significance | 28 |
kg predicted | 28 |
infection control | 28 |
data obtained | 28 |
retrospective review | 28 |
medical patients | 28 |
underlying diseases | 28 |
hypoxic respiratory | 28 |
cell line | 28 |
altman analysis | 28 |
hypoxemic patients | 28 |
bed icu | 27 |
life care | 27 |
phase iii | 27 |
hemodynamic effects | 27 |
total body | 27 |
fatal outcome | 27 |
connective tissue | 27 |
may influence | 27 |
surfactant abnormalities | 27 |
inferior vena | 27 |
secondary endpoints | 27 |
significantly longer | 27 |
study clinical | 27 |
myocardial ischemia | 27 |
capillary barrier | 27 |
early sepsis | 27 |
closely related | 27 |
will also | 27 |
aged years | 27 |
adjunctive therapy | 27 |
therapeutic management | 27 |
receptor expression | 27 |
organ dysfunctions | 27 |
novel therapeutic | 27 |
related acute | 27 |
ventricular failure | 27 |
cohort studies | 27 |
plasma concentration | 27 |
pulmonary capillary | 27 |
fatality rate | 27 |
lymph nodes | 27 |
bronchopulmonary dysplasia | 27 |
several factors | 27 |
ventilation perfusion | 27 |
similar results | 27 |
mean time | 27 |
ml vs | 27 |
corresponding author | 27 |
angiotensin system | 27 |
porcine model | 27 |
infected pneumonia | 27 |
surfactant administration | 27 |
internal medicine | 27 |
unfractionated heparin | 27 |
different levels | 27 |
protein synthesis | 27 |
prognostic factor | 27 |
partial thromboplastin | 27 |
ards according | 27 |
sublingual microcirculation | 27 |
lining fluid | 27 |
corticosteroid use | 27 |
month follow | 27 |
extracellular matrix | 27 |
chronic lung | 27 |
nmba infusion | 27 |
previously published | 27 |
acute liver | 27 |
diaphragm dysfunction | 27 |
within minutes | 27 |
many studies | 27 |
one patients | 27 |
hepatic encephalopathy | 27 |
surgical intervention | 27 |
cell apoptosis | 27 |
group versus | 27 |
overall survival | 27 |
available data | 27 |
hours following | 27 |
severe complications | 27 |
abdominal pain | 27 |
prone ventilation | 27 |
capillary permeability | 26 |
retrospectively reviewed | 26 |
hours post | 26 |
respiratory viral | 26 |
without significant | 26 |
age group | 26 |
requiring intensive | 26 |
venous oxygen | 26 |
remaining patients | 26 |
peep titration | 26 |
respiratory diseases | 26 |
icu treatment | 26 |
ventilation distribution | 26 |
diagnostic accuracy | 26 |
recently published | 26 |
mean sd | 26 |
combination therapy | 26 |
alveolar collapse | 26 |
four groups | 26 |
less likely | 26 |
significantly greater | 26 |
mean blood | 26 |
seb veh | 26 |
high tidal | 26 |
baseline values | 26 |
pulmonary dead | 26 |
two years | 26 |
oxygen radicals | 26 |
cell function | 26 |
remained unchanged | 26 |
whole body | 26 |
severe illness | 26 |
thrombin generation | 26 |
kg pbw | 26 |
breathing pattern | 26 |
perfusion mismatch | 26 |
left ventricle | 26 |
twenty patients | 26 |
cirrhotic patients | 26 |
year survival | 26 |
identify risk | 26 |
vascular injury | 26 |
clinical parameters | 26 |
based therapies | 26 |
birth weight | 26 |
dawley rats | 26 |
spotted fever | 26 |
new insights | 26 |
clinical examination | 26 |
improves survival | 26 |
kg hr | 26 |
secondary bacterial | 26 |
syndrome associated | 26 |
cure rct | 26 |
cardiac surgical | 26 |
may represent | 26 |
per group | 26 |
higher apache | 26 |
variables associated | 26 |
natriuretic peptide | 26 |
cantly higher | 26 |
improve patient | 26 |
induced inflammation | 26 |
medical treatment | 26 |
authors concluded | 26 |
clinical improvement | 26 |
mg day | 26 |
study groups | 26 |
ml cm | 26 |
cell therapies | 26 |
venous extracorporeal | 26 |
systemic corticosteroids | 26 |
group without | 26 |
severe asthma | 26 |
cell adhesion | 26 |
international guidelines | 26 |
blood levels | 26 |
femoral vein | 26 |
wedge pressure | 26 |
nitrogen balance | 26 |
community acquired | 26 |
carotid artery | 26 |
derived mscs | 26 |
least hours | 26 |
sum test | 26 |
fungal infection | 26 |
positive patients | 26 |
study reported | 26 |
day survival | 26 |
patients needed | 26 |
twice daily | 26 |
lung infection | 26 |
ulvwf path | 25 |
hepatocyte growth | 25 |
hospital icu | 25 |
icu days | 25 |
eolia trial | 25 |
pediatric acute | 25 |
transit time | 25 |
pneumonia patients | 25 |
vein thrombosis | 25 |
emergency departments | 25 |
transplant recipients | 25 |
marginated neutrophils | 25 |
chest pain | 25 |
four hours | 25 |
statistical difference | 25 |
lung failure | 25 |
therapeutic approaches | 25 |
fungal infections | 25 |
activated neutrophils | 25 |
term survival | 25 |
one third | 25 |
early corticosteroid | 25 |
lung morphology | 25 |
granulocyte colony | 25 |
animal experiments | 25 |
remains controversial | 25 |
control mice | 25 |
treatment groups | 25 |
working group | 25 |
surgical procedure | 25 |
disease course | 25 |
dioxide removal | 25 |
early postoperative | 25 |
seb thc | 25 |
ards patient | 25 |
serum il | 25 |
proinflammatory cytokine | 25 |
antiviral treatment | 25 |
mainly due | 25 |
early treatment | 25 |
viral replication | 25 |
fi brinogen | 25 |
inspiratory effort | 25 |
care setting | 25 |
expert opinion | 25 |
critical ill | 25 |
ground glass | 25 |
viral rna | 25 |
peritoneal macrophages | 25 |
also recorded | 25 |
critical covid | 25 |
vascular leak | 25 |
requiring invasive | 25 |
negative bacilli | 25 |
patients suffered | 25 |
continuous monitoring | 25 |
regional strain | 25 |
vivo studies | 25 |
surfactant therapy | 25 |
healthy individuals | 25 |
done using | 25 |
may induce | 25 |
drug resistant | 25 |
two days | 25 |
vt ml | 25 |
tissue hypoxia | 25 |
adrenal insufficiency | 25 |
derived extracellular | 25 |
single cell | 25 |
tissue perfusion | 25 |
higher rate | 25 |
carbon monoxide | 25 |
infl uenza | 25 |
narrative review | 25 |
consecutive days | 25 |
superoxide dismutase | 25 |
icu physicians | 25 |
health problem | 25 |
fiberoptic bronchoscopy | 25 |
also associated | 25 |
arterial hypertension | 25 |
spontaneous ventilation | 25 |
bloodstream infections | 24 |
ct findings | 24 |
premature infants | 24 |
confirmed cases | 24 |
neutropenic patients | 24 |
ct imaging | 24 |
cell counts | 24 |
good correlation | 24 |
mitochondrial function | 24 |
predict mortality | 24 |
late phase | 24 |
invasive procedures | 24 |
severe brain | 24 |
selection bias | 24 |
ards treatment | 24 |
trend toward | 24 |
differential expression | 24 |
investigated whether | 24 |
major abdominal | 24 |
years ago | 24 |
main causes | 24 |
missing data | 24 |
severe sars | 24 |
several limitations | 24 |
death among | 24 |
least two | 24 |
postoperative day | 24 |
human immunodeficiency | 24 |
keratinocyte growth | 24 |
blood coagulation | 24 |
respiratory effort | 24 |
kg hour | 24 |
significant proportion | 24 |
data show | 24 |
cortisol levels | 24 |
american college | 24 |
thromboplastin time | 24 |
making process | 24 |
bloodstream infection | 24 |
liver cirrhosis | 24 |
infectious disease | 24 |
main results | 24 |
clinical criteria | 24 |
tyrosine kinase | 24 |
nk cells | 24 |
eff ectiveness | 24 |
ventilatory strategy | 24 |
prolonged icu | 24 |
mean pulmonary | 24 |
low molecular | 24 |
streptococcus pneumoniae | 24 |
factors related | 24 |
donor lungs | 24 |
fluid loading | 24 |
france correspondence | 24 |
deep vein | 24 |
gastric contents | 24 |
adverse outcomes | 24 |
cytokine response | 24 |
serum samples | 24 |
early ards | 24 |
immunodeficiency virus | 24 |
resource utilization | 24 |
related quality | 24 |
chest compressions | 24 |
hypercapnic acidosis | 24 |
weaning protocol | 24 |
immune suppression | 24 |
first study | 24 |
specific treatment | 24 |
multivariate regression | 24 |
syndrome clinical | 24 |
inflammatory state | 24 |
clinical findings | 24 |
patients discharged | 24 |
prospective studies | 24 |
reference introduction | 24 |
patients experienced | 24 |
icu team | 24 |
different clinical | 23 |
roc curves | 23 |
median sofa | 23 |
improve outcomes | 23 |
thrombocytopenic purpura | 23 |
predict outcome | 23 |
deceased patients | 23 |
poor neurological | 23 |
fi brosis | 23 |
epidemiological characteristics | 23 |
related organ | 23 |
left lung | 23 |
lung protection | 23 |
breathing patients | 23 |
typical acute | 23 |
weight heparin | 23 |
practice guideline | 23 |
nutritional status | 23 |
common complication | 23 |
acute interstitial | 23 |
negative impact | 23 |
resistant bacteria | 23 |
endothelial activation | 23 |
develop ards | 23 |
male patients | 23 |
endothelial function | 23 |
predict fluid | 23 |
following criteria | 23 |
microvascular endothelial | 23 |
base excess | 23 |
gastric emptying | 23 |
two main | 23 |
interim analysis | 23 |
system failure | 23 |
chi square | 23 |
recruitment manoeuvre | 23 |
human umbilical | 23 |
oxygen supply | 23 |
human monocytes | 23 |
change significantly | 23 |
venous return | 23 |
study patients | 23 |
oxygen fraction | 23 |
thrombotic thrombocytopenic | 23 |
group patients | 23 |
endothelial progenitor | 23 |
renal disease | 23 |
respiratory treatments | 23 |
ventilation time | 23 |
massive transfusion | 23 |
experimental models | 23 |
ideal body | 23 |
respiratory management | 23 |
recently reported | 23 |
umbilical cord | 23 |
venous ecmo | 23 |
tracheostomy tube | 23 |
natural killer | 23 |
ventricular dysfunction | 23 |
plateau pressures | 23 |
acinetobacter baumanii | 23 |
patients developing | 23 |
two methods | 23 |
often associated | 23 |
risk score | 23 |
uric acid | 23 |
crp levels | 23 |
treated mice | 23 |
artery disease | 23 |
serum albumin | 23 |
remains high | 23 |
protective role | 23 |
pulmonary syndrome | 23 |
outcome scale | 23 |
pk pd | 23 |
patients met | 23 |
neutrophil activation | 23 |
invasive mv | 23 |
syndrome prone | 23 |
plasma exchange | 23 |
one month | 23 |
right atrial | 23 |
ards mortality | 23 |
increased permeability | 23 |
median days | 23 |
treatment failure | 23 |
severe infections | 23 |
data showed | 23 |
prism score | 23 |
gastrointestinal bleeding | 23 |
lower risk | 23 |
saps score | 23 |
barrier regulation | 23 |
neutrophil infiltration | 23 |
secondary infection | 23 |
immune dysregulation | 23 |
injured mice | 23 |
sepsis septic | 23 |
spectrum antibiotics | 23 |
venous catheters | 23 |
wilcoxon rank | 23 |
clinical experience | 23 |
stroke patients | 23 |
respiratory variations | 23 |
femoral artery | 23 |
chain kinase | 23 |
lung recruitability | 23 |
worse outcome | 23 |
average duration | 23 |
san diego | 23 |
ards diagnosis | 23 |
control ventilation | 23 |
mobility group | 23 |
expiratory time | 23 |
vascular smooth | 22 |
ventilatory parameters | 22 |
filtration rate | 22 |
ards induced | 22 |
ecmo weaning | 22 |
may allow | 22 |
lopinavir ritonavir | 22 |
candidate gene | 22 |
prospective multicenter | 22 |
interstitial edema | 22 |
neurological complications | 22 |
oxygenation parameters | 22 |
cells may | 22 |
physical examination | 22 |
lung assist | 22 |
total bilirubin | 22 |
syndrome pulmonary | 22 |
studies demonstrated | 22 |
recent report | 22 |
multicenter cohort | 22 |
arrest patients | 22 |
ii cell | 22 |
ventricular ejection | 22 |
might also | 22 |
paediatric intensive | 22 |
currently available | 22 |
face mask | 22 |
induced endothelial | 22 |
per cent | 22 |
dry weight | 22 |
conventional ventilatory | 22 |
patients also | 22 |
volume index | 22 |
also significantly | 22 |
results demonstrate | 22 |
first line | 22 |
anticoagulant therapy | 22 |
nursing care | 22 |
mast cells | 22 |
coronavirus infections | 22 |
ct images | 22 |
average length | 22 |
antimicrobial resistance | 22 |
different groups | 22 |
vs control | 22 |
neurologic outcome | 22 |
hypertonic saline | 22 |
infection due | 22 |
icu patient | 22 |
may reflect | 22 |
independent factors | 22 |
studies will | 22 |
liver enzymes | 22 |
microcirculatory blood | 22 |
bacterial resistance | 22 |
remains unknown | 22 |
pulmonary compliance | 22 |
extracorporeal circulation | 22 |
chest tube | 22 |
acute hypoxic | 22 |
group will | 22 |
intravenous injection | 22 |
took place | 22 |
lung pathology | 22 |
electronic medical | 22 |
i min | 22 |
free radical | 22 |
acute ischemic | 22 |
upper airway | 22 |
clinical suspicion | 22 |
repeated measures | 22 |
lung safe | 22 |
standard practice | 22 |
group iii | 22 |
posted june | 22 |
dynamic driving | 22 |
negative sepsis | 22 |
defined according | 22 |
host immune | 22 |
zu einer | 22 |
blood transfusions | 22 |
outcome measure | 22 |
syndrome network | 22 |
shockable rhythm | 22 |
future research | 22 |
first group | 22 |
also noted | 22 |
cor pulmonale | 22 |
icu staff | 22 |
hemodynamic stability | 22 |
charlson comorbidity | 22 |
nutrition support | 22 |
bacterial growth | 22 |
electron microscopy | 22 |
complement system | 22 |
pulmonary complications | 22 |
patients within | 22 |
care management | 22 |
critical illnesses | 22 |
illness severity | 22 |
first step | 22 |
time pcr | 22 |
described previously | 22 |
tbi patients | 22 |
severe hypoxaemia | 22 |
arachidonic acid | 21 |
higher doses | 21 |
results patients | 21 |
volume resuscitation | 21 |
clinical aspects | 21 |
expressed genes | 21 |
following injury | 21 |
survival group | 21 |
supplementary information | 21 |
vital capacity | 21 |
cerebrospinal fluid | 21 |
old female | 21 |
expression profiling | 21 |
china clinical | 21 |
ivig group | 21 |
emergency surgery | 21 |
every day | 21 |
experimental data | 21 |
chronic disease | 21 |
intraperitoneal injection | 21 |
multivariable analysis | 21 |
vmtd dit | 21 |
activating factor | 21 |
appropriate treatment | 21 |
ards remains | 21 |
ventricular fibrillation | 21 |
occlusion pressure | 21 |
rank sum | 21 |
clinical symptoms | 21 |
ventilator asynchrony | 21 |
kcal kg | 21 |
young children | 21 |
severe septic | 21 |
infusion rate | 21 |
controlled mode | 21 |
life threatening | 21 |
preclinical studies | 21 |
invasive aspergillosis | 21 |
hepatic dysfunction | 21 |
common causes | 21 |
thrombotic complications | 21 |
neutrophil recruitment | 21 |
frozen plasma | 21 |
twelve patients | 21 |
endotoxic shock | 21 |
airway epithelial | 21 |
pearson correlation | 21 |
inhibitory effect | 21 |
mortality due | 21 |
physical function | 21 |
citrate anticoagulation | 21 |
lower incidence | 21 |
qs qt | 21 |
day post | 21 |
machine learning | 21 |
rat lung | 21 |
pulmonary endothelium | 21 |
primary end | 21 |
comatose patients | 21 |
cardiac arrests | 21 |
ventilation management | 21 |
cd cells | 21 |
target range | 21 |
liquid chromatography | 21 |
past years | 21 |
alcohol abuse | 21 |
prolonged glucocorticoid | 21 |
clinical impact | 21 |
activated partial | 21 |
factors may | 21 |
insulin infusion | 21 |
induced increase | 21 |
following major | 21 |
curve analysis | 21 |
tracheal tube | 21 |
ace receptor | 21 |
dynamic compliance | 21 |
group received | 21 |
macrophage colony | 21 |
gastrointestinal tract | 21 |
improved outcomes | 21 |
much lower | 21 |
current practice | 21 |
continuously monitored | 21 |
metabolic disorders | 21 |
lung elastance | 21 |
low risk | 21 |
days alive | 21 |
received ecmo | 21 |
secondary objectives | 21 |
esophageal balloon | 21 |
patients due | 21 |
study also | 21 |
clot formation | 21 |
inflammatory reactions | 21 |
lung aeration | 21 |
patients develop | 21 |
multiple sclerosis | 21 |
elevated plasma | 21 |
day period | 21 |
tf path | 21 |
respiratory compliance | 21 |
sectional study | 21 |
kg bw | 21 |
elective surgery | 21 |
diffi cult | 21 |
extracorporeal lung | 21 |
ards existence | 21 |
emergency physicians | 21 |
ganz catheter | 21 |
significant change | 21 |
require mechanical | 21 |
nasal oxygen | 21 |
patients following | 21 |
refractory cardiac | 21 |
surfactant proteins | 21 |
early intervention | 21 |
clinical status | 21 |
acid aspiration | 21 |
early use | 20 |
physiological parameters | 20 |
pulmonary gas | 20 |
interventional group | 20 |
serum level | 20 |
myocardial dysfunction | 20 |
cerebral oxygenation | 20 |
one group | 20 |
airway obstruction | 20 |
epithelial barrier | 20 |
imaging findings | 20 |
first case | 20 |
higher icu | 20 |
significant impact | 20 |
data meta | 20 |
bypass grafting | 20 |
undergoing elective | 20 |
ventilator support | 20 |
poorly understood | 20 |
renal impairment | 20 |
may develop | 20 |
trial design | 20 |
ill septic | 20 |
bed medical | 20 |
cognitive impairment | 20 |
xanthine oxidase | 20 |
severe coronavirus | 20 |
induced apoptosis | 20 |
prospectively included | 20 |
electrical activity | 20 |
health status | 20 |
mechanisms underlying | 20 |
hematopoietic stem | 20 |
vessel density | 20 |
preventive measures | 20 |
bacterial meningitis | 20 |
increased survival | 20 |
diaphragm thickness | 20 |
und der | 20 |
data available | 20 |
main reason | 20 |
tissue samples | 20 |
end point | 20 |
french icus | 20 |
low flow | 20 |
acute severe | 20 |
neurological outcomes | 20 |
chart review | 20 |
general intensive | 20 |
early administration | 20 |
white cell | 20 |
analyses will | 20 |
coagulation parameters | 20 |
also performed | 20 |
neonatal respiratory | 20 |
viral loads | 20 |
experimental sepsis | 20 |
directed therapy | 20 |
ethics approval | 20 |
several clinical | 20 |
infl uence | 20 |
national health | 20 |
first dose | 20 |
laboratory parameters | 20 |
mechanical stress | 20 |
sb group | 20 |
icu readmission | 20 |
steroid therapy | 20 |
two weeks | 20 |
will help | 20 |
often used | 20 |
vascular tone | 20 |
injury may | 20 |
chronic pulmonary | 20 |
gram positive | 20 |
group box | 20 |
lactic acidosis | 20 |
variable ventilation | 20 |
metabolic pathways | 20 |
direct examination | 20 |
local ethics | 20 |
resistance index | 20 |
cytokine filter | 20 |
pulmonary pathology | 20 |
potential benefits | 20 |
main objective | 20 |
polymorphonuclear leukocytes | 20 |
stress response | 20 |
may become | 20 |
mean saps | 20 |
drug interactions | 20 |
mean icp | 20 |
results will | 20 |
different cell | 20 |
syndrome date | 20 |
low doses | 20 |
cell population | 20 |
boston cohort | 20 |
inflammatory properties | 20 |
different stages | 20 |
ill icu | 20 |
survival time | 20 |
cerebral ischemia | 20 |
relatively high | 20 |
plasma lactate | 20 |
kg iv | 20 |
healthy lungs | 20 |
emergency care | 20 |
liver injury | 20 |
markedly increased | 20 |
important cause | 20 |
cfu ml | 20 |
fluid infusion | 20 |
nasogastric tube | 20 |
laboratory tests | 20 |
tracheal pressure | 20 |
angiotensin i | 20 |
general anaesthesia | 20 |
lung wet | 20 |
inflection point | 20 |
isolated bacteria | 20 |
significant risk | 20 |
ann intensive | 20 |
highly significant | 20 |
secondary outcome | 20 |
two types | 20 |
massive pulmonary | 20 |
lactic acid | 20 |
performed according | 20 |
last decade | 20 |
multicenter prospective | 20 |
chronic diseases | 20 |
high volume | 20 |
surfactant phospholipids | 20 |
mass spectrometry | 20 |
cd expression | 20 |
useful tool | 20 |
factor associated | 20 |
total lung | 20 |
epithelial lining | 20 |
weight loss | 20 |
randomly allocated | 20 |
among others | 20 |
hiv infection | 20 |
acute illness | 20 |
large amounts | 20 |
mean pao | 20 |
potential risk | 20 |
ali susceptibility | 20 |
ventilator induced | 20 |
peak pressure | 20 |
mouse lungs | 19 |
prolonged weaning | 19 |
ards associated | 19 |
fisher exact | 19 |
complications associated | 19 |
lung units | 19 |
fresh frozen | 19 |
favorable outcome | 19 |
results obtained | 19 |
improve clinical | 19 |
national institute | 19 |
tissue disease | 19 |
positive effects | 19 |
better survival | 19 |
cell extracellular | 19 |
related infections | 19 |
plasma endotoxin | 19 |
arterial thrombosis | 19 |
forced expiratory | 19 |
gel electrophoresis | 19 |
antibiotic use | 19 |
ultraprotective ventilation | 19 |
infected cells | 19 |
volume curve | 19 |
activator receptor | 19 |
upar system | 19 |
male wistar | 19 |
recent advances | 19 |
surgical trauma | 19 |
bl mice | 19 |
dna damage | 19 |
eosinophilic pneumonia | 19 |
muscle strength | 19 |
continuous intravenous | 19 |
clinical variables | 19 |
limited number | 19 |
cell responses | 19 |
positive cells | 19 |
lower levels | 19 |
icu setting | 19 |
first postoperative | 19 |
oxygen transport | 19 |
rat lungs | 19 |
care services | 19 |
kidney function | 19 |
bleeding complications | 19 |
wide variety | 19 |
six months | 19 |
multiple logistic | 19 |
resp score | 19 |
ventilation settings | 19 |